FDA Video: Cardiovascular Problems with Lexiva

GlaxoSmithKline is notifying healthcare professionals that Lexiva (fosamprenavir calcium), a protease inhibitor, has been associated with an increased risk of myocardial infarction and dyslipidemia in HIV infected adults. The company's letter recommends that patients have their cholesterol and triglycerides tested prior to starting therapy with Lexiva and at periodic intervals during treatment with the drug. The letter also recommends treating lipid disorders as required, as well as monitoring and treating other risk factors for cardiovascular disease, such as hypertension, diabetes and smoking.